Secondary Symptoms #6:
Pandemic Fat Cats
There’s another coronavirus. This one, causing horrific swelling in cats, even killing them. Gilead Pharmacueticals might have a drug that can cure this feline coronavirus. Yet, they’re not sharing that drug, possibly because they’re scared it might harm their chances with another drug: Remdesivir. You may have heard of it; it’s the supposed ‘gold standard’ of care for COVID-19. The story of Remdesivir (and of the black market cat drug sibling) reveals how pharmaceutical companies do their research, and the lengths they go to protect their profits.
On this episode of Secondary Symptoms, Gordon interviews Atlantic writer Sarah Zhang about her article on the strange story of feline coronavirus and its possible black market cure, GS-441524. Then, investigative journalist Sharon Lerner of the Intercept tells us about her reporting on GS-441524’s sibling, Remdesivir--no black market necessary. Also on the program, Shannon Brownlee of the Lown Institute, on how to make sense of drug research during the COVID-19 pandemic. Finally, Professor Sergio Sismondo talks about his book Ghost-Managed Medicine, which pulls back the curtain on medical ghostwriting and the other invisible ways that the industry shapes pharmaceutical knowledge.
This episode was funded in part by the Social Science and Humanities Research Council of Canada. This is part of wider project looking at trends in pharmaceutical research and policy. Dr. Joel Lexchin at the University of Toronto and Professor Sergio Sismondo at Queens University in Kingston are the research advisors on that project.
Cited is produced out of the Centre of Ethics at the University of Toronto, which is on the traditional land of Mississaugas of the Credit, the Anishnabeg, the Chippewa, the Haudenosaunee and the Wendat Peoples. Cited is also produced out of the Michael Smith Laboratories at the University of British Columbia -- that’s on the unceded territories of the Musqueam, Squamish, and Tsleil-Waututh Nations.